Generalized Pustular Psoriasis (GPP) Latest Advances

Spesolimab successfully treated acute generalized exanthematous pustulosis in an IL36RN-postive patient.

Journal: JAAD case reports

Published: May 25, 2026

Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis.

Journal: NEJM evidence

Published: April 28, 2026

IL-36-Driven Inflammation in Generalized Pustular Psoriasis: Immunological Insights from Plaque Psoriasis and Implications for Targeted Therapy.

Journal: International journal of molecular sciences

Published: April 17, 2026

The Role of Genetic Testing in the Differential Diagnosis of Pustular Dermatoses: A Pediatric Case of Generalized Pustular Psoriasis Associated with the IL36RN Variant.

Journal: Journal of clinical medicine

Published: April 08, 2026

RSV infection-associated pediatric generalized pustular psoriasis with innate immune activation: a case report.

Journal: Frontiers in immunology

Published: February 11, 2026

Generalized Pustular Psoriasis: Current Treatment and Innovative Therapies.

Journal: Cureus

Published: February 09, 2026

Real-World Evidence of Brodalumab Effectiveness for the Treatment of Psoriasis.

Journal: Journal of drugs in dermatology : JDD

Published: February 05, 2026

Role and clinical significance of PD-L1+ neutrophils in generalized pustular psoriasis

Journal: Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

Published: February 01, 2026

Generalized Pustular Psoriasis in Portugal: Expert Perspectives on Patient Journey, Diagnosis, Therapeutic Goals, and Healthcare Optimization.

Journal: Acta medica portuguesa

Published: January 23, 2026

Targeting the IL-36 Pathway: Spesolimab as a Therapeutic for Acute Flares of Pustular Psoriasis.

Journal: Cureus

Published: January 23, 2026

The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases.

Journal: Allergology international : official journal of the Japanese Society of Allergology

Published: January 20, 2026

The Relative Efficacy of Monotherapies for Palmoplantar Pustulosis and Palmoplantar Psoriasis: A Network Meta-Analysis Study of the Palmoplantar Spectrum.

Journal: Medicina (Kaunas, Lithuania)

Published: January 19, 2026

Generalized Pustular Psoriasis (GPP) Latest Advances

Find the Latest Research About Generalized Pustular Psoriasis (GPP)

Spesolimab successfully treated acute generalized exanthematous pustulosis in an IL36RN-postive patient.

Spesolimab successfully treated acute generalized exanthematous pustulosis in an IL36RN-postive patient.

Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis.

Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis.

IL-36-Driven Inflammation in Generalized Pustular Psoriasis: Immunological Insights from Plaque Psoriasis and Implications for Targeted Therapy.

IL-36-Driven Inflammation in Generalized Pustular Psoriasis: Immunological Insights from Plaque Psoriasis and Implications for Targeted Therapy.

The Role of Genetic Testing in the Differential Diagnosis of Pustular Dermatoses: A Pediatric Case of Generalized Pustular Psoriasis Associated with the IL36RN Variant.

The Role of Genetic Testing in the Differential Diagnosis of Pustular Dermatoses: A Pediatric Case of Generalized Pustular Psoriasis Associated with the IL36RN Variant.

RSV infection-associated pediatric generalized pustular psoriasis with innate immune activation: a case report.

RSV infection-associated pediatric generalized pustular psoriasis with innate immune activation: a case report.

Generalized Pustular Psoriasis: Current Treatment and Innovative Therapies.

Generalized Pustular Psoriasis: Current Treatment and Innovative Therapies.

Real-World Evidence of Brodalumab Effectiveness for the Treatment of Psoriasis.

Real-World Evidence of Brodalumab Effectiveness for the Treatment of Psoriasis.

Role and clinical significance of PD-L1+ neutrophils in generalized pustular psoriasis

Role and clinical significance of PD-L1+ neutrophils in generalized pustular psoriasis

Generalized Pustular Psoriasis in Portugal: Expert Perspectives on Patient Journey, Diagnosis, Therapeutic Goals, and Healthcare Optimization.

Generalized Pustular Psoriasis in Portugal: Expert Perspectives on Patient Journey, Diagnosis, Therapeutic Goals, and Healthcare Optimization.

Targeting the IL-36 Pathway: Spesolimab as a Therapeutic for Acute Flares of Pustular Psoriasis.

Targeting the IL-36 Pathway: Spesolimab as a Therapeutic for Acute Flares of Pustular Psoriasis.

The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases.

The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases.

The Relative Efficacy of Monotherapies for Palmoplantar Pustulosis and Palmoplantar Psoriasis: A Network Meta-Analysis Study of the Palmoplantar Spectrum.

The Relative Efficacy of Monotherapies for Palmoplantar Pustulosis and Palmoplantar Psoriasis: A Network Meta-Analysis Study of the Palmoplantar Spectrum.